Paul Perreault, CSL CEO

M&A sea­son starts ear­ly? CSL seals $11.7B ac­qui­si­tion of Vi­for Phar­ma

Aus­tralia’s CSL is plop­ping down $11.7 bil­lion to ac­quire Vi­for Phar­ma, the Swiss biotech best known for its iron prod­ucts and kid­ney drugs.

While the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.